COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Article view: 179

Article download: 75

IP Indian Journal of Clinical and Experimental Dermatology

Bilastine in higher doses in chronic spontaneous urticaria

Full Text PDF Share on Facebook Share on Twitter

Short Communication

Author Details : Kiran Godse*, Gauri Godse

Volume : 5, Issue : 3, Year : 2019

Article Page : 261-263

Suggest article by email


Objective: To evaluate efficacy and safety of bilastine in higher than usual doses in patients with chronic
spontaneous urticaria (CSU).
Material and Methods: Adult patients with CSU with pruritus and wheal score of more than two
were investigated for complete blood count, urine examination, blood sugar level and thyroid-stimulating
hormone level and treated with bilastine 20 mg (one tablet) before breakfast. In patients who did not show
satisfactory response, dose was increased to 40 mg (two tablets) before breakfast at the end of one week
and 80 mg (two divided doses) at the end of two weeks, if no response seen after the end of one week.
Symptoms were evaluated using urticaria activity score (UAS) and sedation score.
Results: A total of 30 patients (mean age 30.5 years; 56.67% females; baseline mean UAS 5.2) with mean
duration of CSU of 18.9 months were enrolled. Fourteen (51.85%), 10(37.04%) and 2(7.41%) patients
became symptom-free with 20,40, and 80 mg dose of bilastine respectively whereas 1(3.70%) patient not
responding to 80 mg bilastine required cyclosporine. After 1 week of treatment, 3 patients were lost to
follow up. Bilastine was well tolerated without any serious adverse events.
Conclusion: Bilastine is effective and well tolerated in higher (up to 4 times) than normal doses in the
management of chronic spontaneous urticaria.

Keywords: Bilastine, Chronic spontaneous urticaria, Efficacy.

Doi : 10.18231/j.ijced.2019.056

How to cite : Godse K, Godse G, Bilastine in higher doses in chronic spontaneous urticaria. IP Indian J Clin Exp Dermatol 2019;5(3):261-263

Copyright © 2019 by author(s) and IP Indian J Clin Exp Dermatol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (